课题基金 / 基金详情

CD4+ T cells and neoantigens in melanoma immunotherapy.

CD4+ T cells and neoantigens in melanoma immunotherapy.
黑色素瘤免疫治疗中的 CD4 T 细胞和新抗原。
批准号:
10310521
负责人:
Rongfu Wang
金额:
$62.75万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-12-01 至 2025-11-30

项目摘要

项目成果

Rongfu Wang的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 最近的临床试验,使用检查点阻断、抗原特异性T细胞受体(TCR)或CD19嵌合抗原 受体(CAR),在转移性癌症患者中显示了良好的临床效果。然而,尽管 在接受抗PD-1抗体治疗的癌症患者中,超过50%的患者出现了令人印象深刻和持久的临床反应 癌症患者对这种检查站封锁治疗没有反应。基于疫苗和疫苗的免疫治疗 由于缺乏肿瘤特异性靶点,许多实体肿瘤的TCR仍然缺乏。因此,新的目标和 迫切需要发展实体肿瘤免疫治疗方法的战略,包括 黑色素瘤。结合计算机辅助预测算法的全外显子组测序方法 为确定新的癌症患者特异性抗原靶点提供了一个难得的机会 免疫疗法。通过利用下一代测序和肿瘤反应性T细胞,我们最近 发现了许多肿瘤反应性CD4+T细胞和CD8+T细胞识别的新抗原。重要的是,我们 发现一些具有单一TCR的CD4+T克隆可以识别多种新抗原,但不能识别 相应的野生型抗原。最近的临床研究表明,突变特异性的CD4+T细胞可以介导 黑色素瘤和上皮性癌中的肿瘤生长抑制,提示CD4+T细胞在 抑制肿瘤生长,协调整体抗肿瘤免疫。然而,癌症的临床反应 患者与T细胞的转运、持久性和细胞毒能力有关。我们发现,CD4+T细胞 可被重新编程以增强其对癌细胞的细胞毒活性。基于这些前提,我们 假设新抗原特异性T细胞,特别是CD4+T细胞在识别 驱动肿瘤特异性抗肿瘤免疫的新抗原,导致肿瘤消退。这些新抗原可以 从黑色素瘤中被识别出来,并被用作免疫治疗的治疗靶点。我们进一步假设 可以对新抗原特异性的CD4+T细胞进行改造,以提高其T细胞的持久性和细胞溶解能力 联合抗PD-1受体拮抗剂的活性。基于这些前提,我们建议将小说 新抗原,重点是MHC II类新抗原,使用全基因组测序分析和基因 靶向表达系统(Aim 1)。我们进一步计划调查有效的治疗抗肿瘤 免疫优势新抗原和一种新的SAPNANO疫苗技术(AIM)可产生免疫 2)。最后,我们继续我们的研究,以确定SAPNANO疫苗是诱导免疫还是T细胞转移免疫 可以通过免疫检查点阻断或重新编程T细胞来进一步增强,以提高它们的细胞毒性, (目标3)。总而言之,我们建议的研究的成功完成将潜在地改变这一范式 为包括黑色素瘤在内的多种癌症开发新的免疫疗法。
英文摘要
PROJECT ABSTRACT Recent clinical trials, using checkpoint blockade, antigen-specific T cell receptor (TCR) or CD19-chimeric antigen receptor (CAR), have shown promising clinical results for patients with metastatic cancer. However, despite the impressive and durable clinical response in cancer patients treated with anti-PD-1 antibody, more than 50% of cancer patients fail to respond to this checkpoint blockade treatment. Immunotherapy based on vaccines and TCR in many solid tumors is still lacking due to lack of tumor-specific targets. Therefore, new targets and strategies are urgently needed for the development of immunotherapeutic approaches for solid tumors including melanoma. Whole exome sequencing approach in combination with computer-assisted prediction algorithms has provided an exceptional opportunity to identify new patient-specific antigen targets for cancer immunotherapy. By taking advantage of next-generation sequencing and tumor-reactive T cells, we recently identified many neoantigens recognized by tumor-reactive CD4+ T cells as well as CD8+ T cells. Importantly, we found that some of CD4+ T clones with a single TCR could recognize multiple neoantigens, but not the corresponding wild-type antigens. Recent clinical studies show that mutation-specific CD4+ T cells can mediate tumor growth inhibition in melanoma and epithelial cancers, suggesting that CD4+ T cells play a critical role in inhibiting tumor growth and orchestrating overall antitumor immunity. However, clinical responses of cancer patients are correlated with the trafficking, persistence and cytotoxic ability of T cells. We show that CD4+ T cells can be reprogrammed to increase their cytotoxicity activity against cancer cells. Based on these premises, we hypothesize that neoantigen-specific T cells, in particular CD4+ T cells, play an important role in recognizing neoantigens that drive tumor-specific antitumor immunity, leading to tumor regression. These neoantigens can be identified from melanoma and exploited as therapeutic targets for immunotherapy. We further hypothesize that neoantigen-specific CD4+ T cells can be engineered for improving their T cell persistence and cytolytic activity in combination with anti-PD-1 blockade. Based on these premises, we propose to identify novel neoantigens with emphasis on MHC class II neoantigens using genome-wide sequencing analysis and a genetic targeting expression system (Aim 1). We further plan to investigate whether potent therapeutic antitumor immunity can be generated by immunodominant neoantigen and a novel SAPNANO vaccine technology (Aim 2). Finally, we pursue our studies to determine whether SAPNANO vaccine-induced or T cell transfer immunity can be further enhanced by immune checkpoint blockade or reprogramming T cells to improve their cytotoxicity, (Aim 3). In all, the successful completion of our proposed studies will potentially shift the paradigm by the development of novel immunotherapies for many types of cancer including melanoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CD4+ T cells and neoantigens in melanoma immunotherapy.
Transport of Effector T cells and Nano-DC vaccine in Breast Cancer
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
  • 批准号:
    7884621
  • 项目类别:
  • 资助金额:
    $13.73万
  • 财政年份:
    2006
  • 负责人:
    Rongfu Wang
  • 依托单位:
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
  • 批准号:
    7653641
  • 项目类别:
  • 资助金额:
    $25.85万
  • 财政年份:
    2006
  • 负责人:
    Rongfu Wang
  • 依托单位:
海外基金